Ipsen

After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use
Fierce Pharma
Wed, 06/14/23 - 10:22 am
Ipsen
Bylvay
Albireo Pharma
M&A
FDA
liver disease
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Tue, 06/13/23 - 11:37 am
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Pfizer's fortunes overshadow first-quarter dealmaking
EP Vantage
Wed, 04/12/23 - 10:22 am
M&A
Pfizer
Seagen
Sanofi
Provention Bio
AstraZeneca
CinCor
Chiesi
Amryt
Ipsen
Albireo
FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on
Fierce Biotech
Sun, 03/19/23 - 01:34 pm
Ipsen
FDA
palovarotene
fibrodysplasia ossificans progressiva
Ipsen reports positive data from pancreatic ductal adenocarcinoma trial
Clinical Trials Arena
Mon, 01/23/23 - 10:53 am
Ipsen
Onivyde
metastatic pancreatic cancer
pancreatic cancer
clinical trials
Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial
Fierce Biotech
Thu, 01/19/23 - 10:03 am
Ipsen
IRLAB
clinical trials
Parkinson's Disease
mesdopetam
Biopharma’s bolt-on bonanza is set to continue
EP Vantage
Thu, 01/12/23 - 10:18 am
M&A
Amgen
AstraZeneca
Bristol Myers Squibb
GSK
Ipsen
Merck
Pfizer
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
BioPharma Dive
Mon, 01/9/23 - 10:43 am
JPMHC 2023
M&A
AstraZeneca
CinCor
Ipsen
Albireo
Chiesi Farmaceutici
Amryt Pharma
Ipsen's rare disease candidate rejected after mounting setbacks, delays
Fierce Biotech
Fri, 12/30/22 - 10:48 am
Ipsen
FDA
palovarotene
AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure
Fierce Biotech
Wed, 12/14/22 - 10:44 am
Exicure
AbbVie
Ipsen
R&D
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate
Endpoints
Tue, 10/25/22 - 11:09 pm
Ipsen
FDA
fibrodysplasia ossificans progressiva
Go or no go? GSK takes its turn with a novel anemia class
EP Vantage
Fri, 09/30/22 - 10:52 am
FDA
GSK
Amicus Therapeutics
AstraZeneca
Novartis
Supernus
JNJ
Ipsen
Y-mAbs Therapeutics
Ipsen becomes the latest pharma to expand in Ireland, with a $50M investment in its facility in Dublin suburbs
Endpoints
Mon, 09/26/22 - 11:23 pm
Ipsen
Ireland
drug manufacturing
ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some
Fierce Biotech
Sun, 09/11/22 - 10:58 pm
ESMO
Pfizer
Ipsen
EZH2 inhibitors
Epizyme
Trick, or treat? FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug
Endpoints
Mon, 08/22/22 - 08:10 pm
Ipsen
FDA
bone disease
palovarotene
PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde
Endpoints
Wed, 08/3/22 - 10:51 am
Ipsen
Onivyde
small cell lung cancer
clinical trials
Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief
Endpoints
Mon, 08/1/22 - 10:51 am
Ipsen
Marengo Therapeutics
TCR immunotherapy
Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen
Fierce Pharma
Wed, 07/13/22 - 10:09 am
Epizyme
SEC
M&A
Ipsen

Pages